Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

The multivariable and progressive natural history of type 2 diabetes limits the effectiveness
of available glucose-lowering drugs. Constraints imposed by comorbidities (notably …

Obesity is a serious and growing worldwide health challenge. Healthy lifestyle choices are
the foundation of obesity treatment. However, weight loss can lead to physiological …

Type 2 diabetes mellitus (T2DM) is one of the greatest health crises of our time and its
prevalence is projected to increase by> 50% globally by 2045. Currently, 10 classes of …

Insulin is a common treatment option for many patients with type 2 diabetes, and is generally
used late in the natural history of the disease. Its injectable delivery mode, propensity for …

The increasing prevalence, variable pathogenesis, progressive natural history, and
complications of type 2 diabetes emphasise the urgent need for new treatment strategies …

Insulin treatment of individuals with type 1 diabetes has shortcomings and many patients do
not achieve glycaemic and metabolic targets. Consequently, the focus is on novel non …

The increasing prevalence of obesity is contributing substantially to the ongoing epidemic of
type 2 diabetes. Abdominal adiposity, a feature of ectopic fat syndrome, is associated with …

BACKGROUND Diabetes is a deadly and costly disease. The number of adults in the United
States with newly diagnosed diabetes has nearly tripled from 1980 to 2011. At the current …

Background Several pharmacological treatment options are available for type 2 diabetes;
however, many patients do not achieve optimum glycaemic control and therefore new …